Tildrakizumab is under clinical development by Sun Pharma Advanced Research Company and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tildrakizumab’s likelihood of approval (LoA) and phase transition for Psoriatic Arthritis took place on 18 Feb 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tildrakizumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tildrakizumab overview

Tildrakizumab (Ilumya, Ilumetri) is a monoclonal antibody, acts as an immunosuppressant agent. It is formulated as solution for subcutaneous route of administration. Tildrakizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tildrakizumab is under development for the treatment of psoriatic arthritis and plaque psoriasis. It was also under development for ankylosing spondylitis and axial spondyloarthritis.

Sun Pharma Advanced Research Company overview

Sun Pharma Advanced Research Company (SPARC), a subsidiary of Shanghvi Finance Pvt Ltd, is a biopharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatment of cancer and inflammatory diseases. Its research category consists of therapeutic focus, delivery technologies, research programs and research and development pipeline. SPARC’s therapeutic focus comprises oncology, neurodegeneration, ophthalmology, dermatology and abuse-deterrent formulations. The company’s research and development pipeline includes levetiracetam ER, latanoprost BAK Free, salmeterol-fluticasone DPI, baclofen GRS, PICN, brimonidine OD, SDN – 021, SUN – K0706, SUN – 597 Topical, SUN – K0706, minocycline topical, SUN – K0954 and SDP – 037. SPARC is headquartered in Mumbai, Maharashtra, India.

Quick View Tildrakizumab LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Tildrakizumab
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Immunology
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.